Table 3.
Risks of colon cancer recurrences and any additional cancers associated with statin use
| Recurrence | Any cancer event | |||||||
|---|---|---|---|---|---|---|---|---|
| N at riska | Person-years | N | Crude incidence rate per 1000 person-years (95%CI) | Fully adjusted recurrence HR (95%CI)b | N | Crude incidence rate per 1000 person-years (95%CI) | Fully adjusted any cancer HR (95% CI)b | |
| Any statin | ||||||||
| No statin use | 1605 | 7222 | 103 | 14.3 (11.6–17.3) | 1 (ref) | 273 | 37.8 (33.4–42.6) | 1 (ref) |
| Statin use | 937 | 4734 | 49 | 10.4 (7.7–13.7) | 1.09 (0.65–1.85) | 187 | 39.5 (34.0–45.6) | 1.12 (0.85–1.47) |
| By type of statinc | ||||||||
| Atorvastatin use (ref = no atorvastatin use) | 219 | 541 | 6 | 11.1 (4.1–24.1) | 1.56 (0.63–3.87) | 22 | 40.7 (25.5–61.6) | 0.94 (0.59–1.49) |
| Lovastatin use (ref = no lovastatin use) | 425 | 2685 | 28 | 10.4 (6.9–15.1) | 1.47 (0.89–2.43) | 107 | 39.9 (32.7–48.2) | 1.27 (0.98–1.65) |
| Simvastatin use (ref = no simvastatin use) | 683 | 3335 | 30 | 9.0 (6.1–12.8) | 0.94 (0.56–1.57) | 130 | 39.0 (32.6–46.3) | 1.03 (0.79–1.34) |
| Other statin use (ref = no other statin use) | 101 | 329 | 1 | 3.0 (0.1–16.9) | 0.28 (0.04–2.14) | 17 | 51.6 (30.1–82.6) | 1.44 (0.86–2.41) |
aN at risk differs from N in Table 1 because statin exposures are time-varying. Therefore, participants contribute unexposed time until the day they meet exposure criteria
bFully adjusted model included: age and diagnosis year (both using natural cubic splines with knots at tertiles), sex (male/female), stage at diagnosis (I/IIA/IIB/IIIA), study site (KPWA/KPCO), race (white/black/other & unknown), time-varying smoking (yes/no), BMI at diagnosis (< 25.0/25.0–29.9/30.0+ kg/m2), Charlson comorbidity score in the year before diagnosis (0/1/2/3+), statin use in the year before diagnosis (yes/no), antihypertensive use in the year before diagnosis (yes/no), and time-varying antihypertensive use after cohort entry (yes/no)
cEach statin exposure adjusted for all other statin exposures. People could be exposed to multiple types of statins during the study follow-up
Abbreviations: HR hazard ratio, CI confidence interval